PharmAthene, Inc., formed in March 2001 is pursuing its mission to become the premier company worldwide specializing in the development and rapid commercialization of best-in-class medical countermeasures for the multi-billion dollar biodefense industry. By following a strategy of acquiring leading compounds and technologies focused only on high priority medical countermeasures solutions identified by the United States and other governments as urgent to procure, PharmAthene has built a solid product pipeline and a strong reputation within the industry. Up to more than $550 million in United States government contract and funding commitments have been awarded to support the Company’s current product development programs.
About Virtual Biosecurity Center
